Related Experiment Video
Updated: May 11, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Bleeding events associated with novel anticoagulants: a case series
Sam Mirzaee1, Tara Thi Thien Tran, John Amerena
1Barwon Health, Geelong Hospital, Victoria, Australia.
Novel anticoagulants offer alternatives to warfarin for stroke reduction in non-valvular atrial fibrillation (NVAF). Careful patient selection is key to minimizing bleeding risks with these new oral anticoagulants.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Warfarin was the primary oral anticoagulant for stroke prevention in non-valvular atrial fibrillation (NVAF).
- Warfarin effectively reduces stroke rates but poses risks of serious bleeding and challenges in maintaining the international normalized ratio (INR) within the therapeutic range.
Observation:
- The advent of novel oral anticoagulants (NOACs) provides feasible alternatives to warfarin.
- NOACs aim to decrease stroke rates in high-risk NVAF patients.
Findings:
- NOACs represent a significant advancement in anticoagulant therapy since warfarin's introduction.
- These agents offer a new therapeutic option for managing stroke risk in NVAF.
Implications:
- Proper patient selection is crucial for minimizing adverse bleeding events with NOACs.
- The availability of NOACs necessitates a re-evaluation of stroke prevention strategies in NVAF.
- Further research may focus on comparative effectiveness and safety profiles of different NOACs.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

